{"resourceType":"CodeSystem","id":"research-study-phase","meta":{"lastUpdated":"2023-04-01T06:23:11.471+11:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablecodesystem"]},"text":{"status":"generated","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>This code system <code>http://hl7.org/fhir/research-study-phase</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">n-a<a name=\"research-study-phase-n-a\"> </a></td><td>N/A</td><td>Trials without phases (for example, studies of devices or behavioral interventions).</td></tr><tr><td style=\"white-space:nowrap\">early-phase-1<a name=\"research-study-phase-early-phase-1\"> </a></td><td>Early Phase 1</td><td>Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.</td></tr><tr><td style=\"white-space:nowrap\">phase-1<a name=\"research-study-phase-phase-1\"> </a></td><td>Phase 1</td><td>Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.</td></tr><tr><td style=\"white-space:nowrap\">phase-1-phase-2<a name=\"research-study-phase-phase-1-phase-2\"> </a></td><td>Phase 1/Phase 2</td><td>Trials that are a combination of phases 1 and 2.</td></tr><tr><td style=\"white-space:nowrap\">phase-2<a name=\"research-study-phase-phase-2\"> </a></td><td>Phase 2</td><td>Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.</td></tr><tr><td style=\"white-space:nowrap\">phase-2-phase-3<a name=\"research-study-phase-phase-2-phase-3\"> </a></td><td>Phase 2/Phase 3</td><td>Trials that are a combination of phases 2 and 3.</td></tr><tr><td style=\"white-space:nowrap\">phase-3<a name=\"research-study-phase-phase-3\"> </a></td><td>Phase 3</td><td>Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.</td></tr><tr><td style=\"white-space:nowrap\">phase-4<a name=\"research-study-phase-phase-4\"> </a></td><td>Phase 4</td><td>Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.</td></tr></table></div>"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"},{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status","valueCode":"trial-use"},{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm","valueInteger":0}],"url":"http://hl7.org/fhir/research-study-phase","version":"5.0.0-cibuild","name":"ResearchStudyPhase","title":"ResearchStudy Phase Code System","status":"active","experimental":false,"date":"2022-05-15T16:55:11.085+11:00","publisher":"HL7 (FHIR Project)","contact":[{"telecom":[{"system":"url","value":"http://hl7.org/fhir"},{"system":"email","value":"fhir@lists.hl7.org"}]}],"description":"Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.","jurisdiction":[{"coding":[{"system":"http://unstats.un.org/unsd/methods/m49/m49.htm","code":"001","display":"World"}]}],"caseSensitive":true,"valueSet":"http://hl7.org/fhir/ValueSet/research-study-phase","content":"complete","concept":[{"code":"n-a","display":"N/A","definition":"Trials without phases (for example, studies of devices or behavioral interventions)."},{"code":"early-phase-1","display":"Early Phase 1","definition":"Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0."},{"code":"phase-1","display":"Phase 1","definition":"Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients."},{"code":"phase-1-phase-2","display":"Phase 1/Phase 2","definition":"Trials that are a combination of phases 1 and 2."},{"code":"phase-2","display":"Phase 2","definition":"Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks."},{"code":"phase-2-phase-3","display":"Phase 2/Phase 3","definition":"Trials that are a combination of phases 2 and 3."},{"code":"phase-3","display":"Phase 3","definition":"Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug."},{"code":"phase-4","display":"Phase 4","definition":"Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use."}]}